• SENSEX
    NIFTY 50
Business

Novartis' patent on diabetes drug Vildagliptin expires tomorrow, prices to fall by 60%

Updated : December 09, 2019 02:55 PM IST

Vildagliptin is a part of a class of diabetes medications called dipeptidyl peptidase IV or DPP4 inhibitors.
Novartis’ patent on Vildagliptin is expiring on December 9, 2019, and companies can sell its generic version from tomorrow.
Novartis' patent on diabetes drug Vildagliptin expires tomorrow, prices to fall by 60%

You May Also Like

Live TV
Advertisement